Stocks-CHRS-Coherus Biosciences Inc

CHRS Coherus Biosciences Inc

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Coherus Biosciences Inc's revenues decreased by 35.37% and amounted to 211.04M. Net income decreased by 1.62% to -291.75M. Net assets decreased by 240.62% to -137.42M and EPS increased from -3.81 to -3.76.
CHRS's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
55.87%
Net Profit Margin
-43.29%
Operating Margin
-85.70%
Return On Investment
-23.13%